Oesophago-gastric cancer: assessment and management in adults

Resource impact statement

The 2023 update to NICE's guideline on oesophago-gastric cancer replaces the former version published in 2018. The guideline update has:

• reviewed the evidence on the palliative management of luminal obstruction with no curative intent for adults with oesophageal or gastro-oesophageal junctional cancer.
• made new recommendations.

We expect that the resource impact of this update:

• for any single guideline recommendation in England will be less than £1 million per year (or approximately £1,800 per 100,000 population, based on a population for England of 56.6 million people) and
• for implementing the whole guideline in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 56.6 million people).

This is because the population size is small and practice may not change substantially from these recommendations. However there may be a small cost saving from the recommendations if not currently implemented by reducing the number of external beam radiotherapy procedures after stenting and the number of different treatments that most people receive.

Oesophago gastric services are commissioned by integrated care boards and NHS England for cancer drugs. Providers are NHS hospital trusts.